Cite
HARVARD Citation
Barnett, J. et al. (2013). Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. Cancer. 119 (20), pp. 3653-3661. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Barnett, J. et al. (2013). Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. Cancer. 119 (20), pp. 3653-3661. [Online].